Journal of the National Cancer Center最新文献

{"title":"Cancer incidence and mortality in China, 2022","authors":"Bingfeng Han ,&nbsp;Rongshou Zheng ,&nbsp;Hongmei Zeng ,&nbsp;Shaoming Wang ,&nbsp;Kexin Sun ,&nbsp;Ru Chen ,&nbsp;Li Li ,&nbsp;Wenqiang Wei ,&nbsp;Jie He","doi":"10.1016/j.jncc.2024.01.006","DOIUrl":"10.1016/j.jncc.2024.01.006","url":null,"abstract":"<div><h3>Background</h3><p>The National Cancer Center (NCC) of China regularly reports the nationwide statistics on cancer incidence and mortality in China. The International Agency for Research on Cancer (IARC) calculates and publishes the cancer burden of countries around the world every two years. To ensure consistency between the actual surveillance data in China and the data published by IARC, NCC has received approval from the National Health Commission and IARC to simultaneously release the cancer burden data for China in GLOBOCAN 2022.</p></div><div><h3>Methods</h3><p>There were a total of 700 registries reporting high-quality data on cancer incidence and mortality across China in 2018, of which 106 registries with continuous monitoring from 2010 to 2018 were used to establish an age-period-cohort model to simulate the trend of cancer incidence and mortality and to estimate the incidence and mortality in China in 2022. In addition, we analyzed the temporal trends of age-standardized cancer incidence and mortality from 2000 to 2018 using data from 22 continuous cancer registries.</p></div><div><h3>Results</h3><p>It was estimated about 4,824,700 new cancer cases and 2,574,200 new cancer deaths occurred in China in 2022. Cancers of the lung, colon-rectum, thyroid, liver and stomach were the top five cancer types, accounting for 57.42% of new cancer cases. Cancers of the lung, liver, stomach, colon-rectum and esophagus were the five leading causes of cancer deaths, accounting for 67.50% of total cancer deaths. The crude rate and age-standardized incidence rate (ASIR) were 341.75 per 100,000 and 201.61 per 100,000, respectively. The crude mortality rate was 182.34 per 100,000 and the age-standardized mortality rate (ASMR) was 96.47 per 100,000. The ASIR of all cancers combined increased by approximately 1.4% per year during 2000–2018, while the ASMR decreased by approximately 1.3% per year. We observed decreasing trends in ASIR and ASMR for cancers of the esophagus, stomach, and liver, whereas the ASIR increased significantly for cancers of the thyroid, prostate, and cervix.</p></div><div><h3>Conclusions</h3><p>Cancer remains a major public health concern in China, with a cancer profile that reflects the coexistence of developed and developing regions. Sustained implementation of prevention and control measures has resulted in significant reductions in the incidence and mortality rates of certain historically high incidence cancers, such as esophageal, stomach and liver cancers. Adherence to the guidelines of the Healthy China Action Plan and the Cancer Prevention and Control Action Plan, along with continued efforts in comprehensive risk factor control, cancer screening, early diagnosis and treatment, and standardization of diagnostic and therapeutic protocols, are key strategies to effectively mitigate the increasing cancer burden by 2030.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 1","pages":"Pages 47-53"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000061/pdfft?md5=476239329acfd49eee62814ca1604208&pid=1-s2.0-S2667005424000061-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139884006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating tumor DNA as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis","authors":"Na'na Guo ,&nbsp;Qingxin Zhou ,&nbsp;Xiaowei Chen ,&nbsp;Baoqi Zeng ,&nbsp;Shanshan Wu ,&nbsp;Hongmei Zeng ,&nbsp;Feng Sun","doi":"10.1016/j.jncc.2024.01.003","DOIUrl":"10.1016/j.jncc.2024.01.003","url":null,"abstract":"<div><h3>Objective</h3><p>Circulating tumor DNA (ctDNA) is increasingly being used as a potential prognosis biomarker in patients of breast cancer. This review aims to assess the clinical value of ctDNA in outcome prediction in breast cancer patients throughout the whole treatment cycle.</p></div><div><h3>Methods</h3><p>PubMed, Web of Science, Embase, Cochrane Library, Scopus, and clinical trials.gov were searched from January 2016 to May 2022. Conference abstracts published in last three years were also included. The following search terms were used: ctDNA OR circulating tumor DNA AND breast cancer OR breast carcinoma. Only studies written in English languages were included. The following pre-specified criteria should be met for inclusion: (1) observational studies (prospective or retrospective), randomized control trials, case-control studies and case series studies; (2) patients with breast cancer; (3) ctDNA measurement; (4) clinical outcome data such as objective response rate (ORR), pathological complete response (pCR), relapse-free survival (RFS), overall survival (OS), and so on. The random-effect model was preferred considering the potential heterogeneity across studies. The primary outcomes included postoperative short-term outcomes (ORR and pCR) and postoperative long-term outcomes (RFS, OS, and relapse). Secondary outcomes focused on ctDNA detection rate.</p></div><div><h3>Results</h3><p>A total of 30 studies, comprising of 19 cohort studies, 2 case-control studies and 9 case series studies were included. The baseline ctDNA was significantly negatively associated with ORR outcome (Relative Risk [RR] = 0.65, 95% confidence interval [CI]: 0.50–0.83), with lower ORR in the ctDNA-positive group than ctDNA-negative group. ctDNA during neoadjuvant therapy (NAT) treatment was significantly associated with pCR outcomes (Odds Ratio [OR] = 0.15, 95% CI: 0.04–0.54). The strong association between ctDNA and RFS or relapse outcome was significant across the whole treatment period, especially after the surgery (RFS: Hazard Ratio [HR] = 6.74, 95% CI: 3.73–12.17; relapse outcome: RR = 7.11, 95% CI: 3.05–16.53), although there was heterogeneity in these results. Pre-operative and post-operative ctDNA measurements were significantly associated with OS outcomes (pre-operative: HR = 2.03, 95% CI: 1.12–3.70; post-operative: HR = 6.03, 95% CI: 1.31–27.78).</p></div><div><h3>Conclusions</h3><p>In this review, ctDNA measurements at different timepoints are correlated with evaluation indexes at different periods after treatment. The ctDNA can be used as an early potential postoperative prognosis biomarker in breast cancer, and also as a reference index to evaluate the therapeutic effect at different stages.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 1","pages":"Pages 63-73"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000036/pdfft?md5=c426808e2efe4aa77a7110222956a6a4&pid=1-s2.0-S2667005424000036-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139634421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The development and implementation of pathological parameters and molecular testing impact prognosis of colorectal adenocarcinoma","authors":"Midie Xu ,&nbsp;Yaqi Li ,&nbsp;Yingxue Liu ,&nbsp;Jinjia Chang ,&nbsp;Changming Zhou ,&nbsp;Weiwei Weng ,&nbsp;Hui Sun ,&nbsp;Cong Tan ,&nbsp;Xin Wang ,&nbsp;Xu Wang ,&nbsp;Meng Zhang ,&nbsp;Shujuan Ni ,&nbsp;Lei Wang ,&nbsp;Yu Yang ,&nbsp;Xiaoyan Zhou ,&nbsp;Junjie Peng ,&nbsp;Dan Huang ,&nbsp;Weiqi Sheng","doi":"10.1016/j.jncc.2024.02.001","DOIUrl":"10.1016/j.jncc.2024.02.001","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;This study aims to analyze how changes in pathological diagnosis practice and molecular detection technology have affected clinical outcomes for colorectal cancer (CRC) patients in Fudan University Shanghai Cancer Center (FUSCC).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;This retrospective cohort study analyzed 21,141 pathologically confirmed CRC cases diagnosed at FUSCC from 2008 to 2020. Patients were divided into five groups for different analytical purposes: (1) the before vs. since 2014 groups to analyze the influence of the changes in the classification criteria of pT3 and pT4 staging on the survival of patients; (2) the partial vs. total mesorectal excision (TME) groups to analyze whether evaluation of completeness of the mesorectum have impact on the survival of patients; (3) the tumor deposit (TD)(+)N0 vs. TD(+)N1c groups to analyze the influence of the changes in the pN staging on the survival of patients with positive TD and negative regional lymph node metastasis (LNM); (4) the before vs. since 2013 groups to analyze the influence of the changes in the testing process of deficient mismatch repair on the survival of patients; and (5) the groups with vs. without RAS/BRAF gene mutation testing to analyze the influence of these testing on the survival of patients. Patients’ clinicopathological parameters, including age at diagnosis, sex, tumor size, location, differentiation, mucinous subtype, TD, lymphovascular invasion, perineural invasion, tumor depth, LNM and distant metastasis, and tumor-node-metastasis (TNM) stage, were compared between groups. Kaplan-Meier analysis with log rank method was performed for patients’ overall survival (OS) and disease-free survival (DFS) analyses.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;In pathological reports, there were three parameter changes that impacted patient outcomes. Firstly, changes in the pT staging criteria led to a shift of the ratio of patients with stage pT3 to stage pT4 from 1: 110.9 to 1: 0.26. In comparison to patients admitted before 2014 (&lt;em&gt;n&lt;/em&gt; = 4,754), a significant difference in prognosis between pT3 and pT4 stages was observed since 2014 (&lt;em&gt;n&lt;/em&gt; = 9,965). Secondly, we began to evaluate the completeness of the mesorectum since 2016. As a result, 91.0% of patients with low rectal cancer underwent TME (&lt;em&gt;n&lt;/em&gt; = 4,111) surgery, and patients with TME had significantly better OS compared with partial mesorectal excision (PME, &lt;em&gt;n&lt;/em&gt; = 409). Thirdly, we began to stage TD (+) LNM (-) as N1c since 2017. The results showed that N1c (&lt;em&gt;n&lt;/em&gt; = 127) but not N0 (&lt;em&gt;n&lt;/em&gt; = 39) can improve the prognosis of patients without LNM and distal metastasis. In molecular testing, there have been three and five iterations of updates regarding mismatch repair (MMR)/microsatellite instability (MSI) status and RAS/BRAF gene mutation detection, respectively. The standardization of MMR status testing has sharply decreased the proportion of deficient MMR (dMMR) patients (from ","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 1","pages":"Pages 74-85"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000073/pdfft?md5=9884d103f18f07d0cc296a30ae7fe3c7&pid=1-s2.0-S2667005424000073-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139876528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning model based on primary tumor to predict lymph node status in clinical stage IA lung adenocarcinoma: a multicenter study","authors":"Li Zhang ,&nbsp;Hailin Li ,&nbsp;Shaohong Zhao ,&nbsp;Xuemin Tao ,&nbsp;Meng Li ,&nbsp;Shouxin Yang ,&nbsp;Lina Zhou ,&nbsp;Mengwen Liu ,&nbsp;Xue Zhang ,&nbsp;Di Dong ,&nbsp;Jie Tian ,&nbsp;Ning Wu","doi":"10.1016/j.jncc.2024.01.005","DOIUrl":"10.1016/j.jncc.2024.01.005","url":null,"abstract":"<div><h3>Objective</h3><p>To develop a deep learning model to predict lymph node (LN) status in clinical stage IA lung adenocarcinoma patients.</p></div><div><h3>Methods</h3><p>This diagnostic study included 1,009 patients with pathologically confirmed clinical stage T1N0M0 lung adenocarcinoma from two independent datasets (699 from Cancer Hospital of Chinese Academy of Medical Sciences and 310 from PLA General Hospital) between January 2005 and December 2019. The Cancer Hospital dataset was randomly split into a training cohort (559 patients) and a validation cohort (140 patients) to train and tune a deep learning model based on a deep residual network (ResNet). The PLA Hospital dataset was used as a testing cohort to evaluate the generalization ability of the model. Thoracic radiologists manually segmented tumors and interpreted high-resolution computed tomography (HRCT) features for the model. The predictive performance was assessed by area under the curves (AUCs), accuracy, precision, recall, and F1 score. Subgroup analysis was performed to evaluate the potential bias of the study population.</p></div><div><h3>Results</h3><p>A total of 1,009 patients were included in this study; 409 (40.5%) were male and 600 (59.5%) were female. The median age was 57.0 years (inter-quartile range, IQR: 50.0–64.0). The deep learning model achieved AUCs of 0.906 (95% CI: 0.873–0.938) and 0.893 (95% CI: 0.857–0.930) for predicting pN0 disease in the testing cohort and a non-pure ground glass nodule (non-pGGN) testing cohort, respectively. No significant difference was detected between the testing cohort and the non-pGGN testing cohort (<em>P</em> = 0.622). The precisions of this model for predicting pN0 disease were 0.979 (95% CI: 0.963–0.995) and 0.983 (95% CI: 0.967–0.998) in the testing cohort and the non-pGGN testing cohort, respectively. The deep learning model achieved AUCs of 0.848 (95% CI: 0.798–0.898) and 0.831 (95% CI: 0.776–0.887) for predicting pN2 disease in the testing cohort and the non-pGGN testing cohort, respectively. No significant difference was detected between the testing cohort and the non-pGGN testing cohort (<em>P</em> = 0.657). The recalls of this model for predicting pN2 disease were 0.903 (95% CI: 0.870–0.936) and 0.931 (95% CI: 0.901–0.961) in the testing cohort and the non-pGGN testing cohort, respectively.</p></div><div><h3>Conclusions</h3><p>The superior performance of the deep learning model will help to target the extension of lymph node dissection and reduce the ineffective lymph node dissection in early-stage lung adenocarcinoma patients.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 3","pages":"Pages 233-240"},"PeriodicalIF":7.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266700542400005X/pdfft?md5=07e3c41e80da73446c9241c22399a44e&pid=1-s2.0-S266700542400005X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-T in cancer therapeutics and updates","authors":"","doi":"10.1016/j.jncc.2024.01.001","DOIUrl":"10.1016/j.jncc.2024.01.001","url":null,"abstract":"<div><p>Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking approach in cancer treatment, utilizing the immune system's capabilities to combat malignancies. This innovative therapy involves extracting T-cells from a patient's blood, genetically modifying them to target specific cancer cells, and reinfusing them back into the patient's body. The genetically modified T-cells then seek out and eliminate cancer cells, offering a promising therapeutic strategy. Since its initial approval in 2017, CAR-T therapy has witnessed remarkable advancements and updates. Notably, CAR-T therapy, which was initially developed for hematological malignancies, has expanded its scope to target solid tumors. Currently, clinical trials are underway to explore the efficacy of CAR-T therapy in treating various solid tumors, such as lung cancer, breast cancer, and ovarian cancer. These trials hold great potential to revolutionize cancer treatment and provide new hope to patients with challenging-to-treat solid tumors. In this mini-review, we present an overview of CAR-T therapy's mechanisms, emphasizing its role in targeting cancer cells and the potential therapeutic benefits. Additionally, we discuss the recent progress and updates in CAR-T therapy, particularly its application in treating solid tumors, and highlight the ongoing clinical trials aimed at broadening its therapeutic horizon. The evolving landscape of CAR-T therapy signifies a promising direction in cancer therapeutics, with the potential to revolutionize the treatment of both hematological and solid tumor malignancies.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 3","pages":"Pages 189-194"},"PeriodicalIF":7.6,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000012/pdfft?md5=506eafe8fb2394dd960f5b928f7d0cca&pid=1-s2.0-S2667005424000012-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139454713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial note to “Tumor microenvironment-based signatures distinguish intratumoral heterogeneity, prognosis, and immunogenomic features of clear cell renal cell carcinoma” [J Natl Cancer Cent. 2023;3(3):236-249]","authors":"","doi":"10.1016/j.jncc.2024.02.003","DOIUrl":"10.1016/j.jncc.2024.02.003","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 2","pages":"Page 176"},"PeriodicalIF":7.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000103/pdfft?md5=85ba194f77ff5f7d5b2300f025849e03&pid=1-s2.0-S2667005424000103-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140089478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)","authors":"Jianchun Duan ,&nbsp;Wenfeng Fang ,&nbsp;Hairong Xu ,&nbsp;Jinliang Wang ,&nbsp;Yuan Chen ,&nbsp;Yi Ding ,&nbsp;Xiaorong Dong ,&nbsp;Yun Fan ,&nbsp;Beili Gao ,&nbsp;Jie Hu ,&nbsp;Yan Huang ,&nbsp;Cheng Huang ,&nbsp;Dingzhi Huang ,&nbsp;Wenhua Liang ,&nbsp;Lizhu Lin ,&nbsp;Hui Liu ,&nbsp;Zhiyong Ma ,&nbsp;Meiqi Shi ,&nbsp;Yong Song ,&nbsp;Chuanhao Tang ,&nbsp;Jie Wang","doi":"10.1016/j.jncc.2023.08.004","DOIUrl":"10.1016/j.jncc.2023.08.004","url":null,"abstract":"<div><p>Lung cancer is the leading cause of cancer-related deaths worldwide. Bone is a common metastatic site of lung cancer, about 50% of bone metastatic patients will experience skeletal related events (SREs). SREs not only seriously impact the quality of life of patients, but also shorten their survival time. The treatment of bone metastasis requires multi-disciplinary therapy (MDT) and development of individualized treatment plan. In order to standardize the diagnosis and treatment of bone metastasis in lung cancer, the expert group of the MDT Committee of the Chinese Medical Doctor Association has developed the expert consensus on the diagnosis and treatment of lung cancer bone metastasis.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 4","pages":"Pages 256-265"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005423000492/pdfft?md5=665a7ce34e38970b91bbf5d9106b2523&pid=1-s2.0-S2667005423000492-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47310586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted drug delivery systems for pancreatic ductal adenocarcinoma: overcoming tumor microenvironment challenges with CAF-specific nanoparticles","authors":"Xinming Su ,&nbsp;Zehua Wang ,&nbsp;Shiwei Duan","doi":"10.1016/j.jncc.2023.10.001","DOIUrl":"10.1016/j.jncc.2023.10.001","url":null,"abstract":"<div><p>Pancreatic ductal adenocarcinoma (PDAC) stands as a profoundly heterogeneous and aggressive malignancy, manifesting a discouragingly limited response to conventional therapeutic interventions. Within the intricate tapestry of the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) emerge as pivotal constituents, wielding the capacity to propel the malignant attributes of neoplastic cells while bolstering their deftness in thwarting treatments. The rapid evolution of nanomedicinal technologies ushers in fresh avenues for therapeutic paradigms meticulously honed to target CAFs. Notably, a recent proposition by Yuan et al. introduces a PDAC treatment strategy metaphorically akin to “shooting fish in a barrel.” By adeptly capitalizing on the spatial distribution of the CAF barricade encircling the tumor, this innovative approach orchestrates a metamorphosis of CAFs, transitioning them from impediments to drug delivery into reservoirs of therapeutic agents. The resultant outcome, an augmentation of chemotherapy and immunotherapy efficacy, attests to the transformative potential of this concept. The study not only bequeaths novel insights and methodologies to surmount barriers in drug delivery for tumor treatment but also holds promise in elevating the precision, efficacy, and safety of tailored therapeutic regimens. Within this discourse, we meticulously evaluate Yuan et al.'s research, scrutinizing its merits and limitations, and cast a forward-looking gaze upon the formulation, validation of efficacy, and clinical translation of nanomedicines targeting CAFs.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 4","pages":"Pages 306-309"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005423000662/pdfft?md5=cd4411eb0bff5c8aa9f587bcde1e4a0f&pid=1-s2.0-S2667005423000662-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135705752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mutation-based circulating tumor DNA detection approach to monitoring the therapy response in breast cancer","authors":"Jiaqi Liu ,&nbsp;Yansong Huang ,&nbsp;Xiang Wang","doi":"10.1016/j.jncc.2023.08.006","DOIUrl":"10.1016/j.jncc.2023.08.006","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 4","pages":"Pages 254-255"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005423000613/pdfft?md5=bea146871540cffa0bb6246ab56e8928&pid=1-s2.0-S2667005423000613-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49518953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)","authors":"Bu Hong ,&nbsp;Fan Ying ,&nbsp;Fan Zhaoqing ,&nbsp;Hu Xichun ,&nbsp;Li Man ,&nbsp;Li Qiao ,&nbsp;Liao Ning ,&nbsp;Luo Ting ,&nbsp;Nie Jianyun ,&nbsp;Pan Yueyin ,&nbsp;Qi Xiaowei ,&nbsp;Shao Zhimin ,&nbsp;Song Guohong ,&nbsp;Sun Tao ,&nbsp;Teng Yue-e ,&nbsp;Tong Zhongsheng ,&nbsp;Wang Jiayu ,&nbsp;Wang Shusen ,&nbsp;Wang Xue ,&nbsp;Wang Yongsheng ,&nbsp;Zhao Jiuda","doi":"10.1016/j.jncc.2023.09.002","DOIUrl":"10.1016/j.jncc.2023.09.002","url":null,"abstract":"<div><p>Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2-low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistochemistry [IHC] 1+, or IHC2+/in situ hybridization [ISH]-) breast cancer, HER2-low may become a new subtype of targeted therapy for breast cancer. The expert committee formulated this consensus based on the current clinical studies and clinical medication experience. The current consensus is the collaborative work of an interdisciplinary working group, including experts in the fields of pathology and oncology. The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer, thereby prolonging the overall survival of patients.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"3 4","pages":"Pages 266-272"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005423000650/pdfft?md5=59cb1c043eec46b7b4255c534bcabea6&pid=1-s2.0-S2667005423000650-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135588288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}